Dr. Michi M. Shinohara, MD

Dr. Shinohara practices at Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center.

Dr. Shinohara's NPI, 1750491650, was assigned on August 30, 2006. Dr. Shinohara graduated from University of Washington School of Medicine in 2002. Dr. Shinohara holds Washington license MD00045047.

Dr. Shinohara's primary practice is Fred Hutchinson Cancer Center, at 825 Eastlake Avenue East, Seattle, WA 98109.

Dr. Shinohara's primary practice is Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center. Dr. Shinohara is also affiliated with UW Medical Center - Montlake. The medical group on file is UW Physicians. Dmand AI also links Dr. Shinohara to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shinohara practices, 4 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Shinohara's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Shinohara is licensed in Washington.

CMS data shows 968 Medicare services from Dr. Shinohara across 14 procedure codes in 2024, for 484 Medicare patients. Medicare paid $39,082 for them.

CMS counts 484 Medicare patients who saw Dr. Shinohara in 2024. The largest group is 65 to 74, with 202 patients. 68% of them have high cholesterol, and 65% have high blood pressure. 7% are also on Medicaid. Their average risk score is 1.57, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shinohara's median patient age at 66, with 49% women.

In 2024, Dr. Shinohara wrote 344 Medicare Part D claims for 70 patients. 94% of them were for generic drugs. CMS names the drug for 215 of them, across 7 drugs with 11 or more claims each, at $98,418 in total drug cost. In 2023, CMS named 141 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Shinohara for performance year 2024, reported through an alternative payment model (APM). Dr. Shinohara accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Shinohara as offering telehealth. CMS counts 45 procedures of removal of skin lesions by Dr. Shinohara, more than 71% of the clinicians it reports for that procedure.

Dmand AI links 109 papers to Dr. Shinohara, published from 2009 to 2025. 2022 was the busiest year, with 12. The most frequent topics are Skin Neoplasms, Lymphoma, T-Cell, Cutaneous and Dermatology. Dr. Shinohara has published most often in J Cutan Pathol. Dr. Shinohara's most frequent co-authors are Paul Tuan-Xuan Nghiem, Shailender Bhatia, MD and Rosalie Elenitsas, MD.

Dmand AI links Dr. Shinohara to 3 clinical trials. 1 is still active or recruiting. Conditions studied include Mycosis Fungoides, Pemphigus and Pruritus.

CMS Open Payments shows 6 general payments to Dr. Shinohara from 2 drug and device companies from 2022 to 2025. Consulting fees make up the largest share, 79% of the total. Kyowa Kirin, Inc. paid the most, $1,878.

Dr. Shinohara graduated from University of Washington School of Medicine in 2002.